Effect of gemtuzumab ozogamicin on acute myeloid leukaemia blast cells in vitro, as a single agent and combined with other cytotoxic agents

被引:12
|
作者
Morris, K. L. [1 ]
Adams, J. A. [1 ]
Yin, J. A. Liu [1 ]
机构
[1] Univ Manchester, Manchester Royal Infirm, Dept Clin Haematol, Manchester M13 9WL, Lancs, England
关键词
gemtuzumab ozogamicin (mylotarg); acute myeloid leukaemia; apoptosis; co-incubation; multi drug resistance;
D O I
10.1111/j.1365-2141.2006.06326.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The effect of gemtuzumab ozogamicin (GO) alone, or combined with low-dose cytarabine or etoposide, on the proliferation of acute myeloid leukaemia blast cells in vitro was investigated. GO alone induced a dose-dependent inhibition of proliferation although an increase in apoptosis was only seen in a minority of patients. A correlation was found between PgP function and GO sensitivity but not between CD33 or PgP expression and GO. Combinations of GO with varying concentrations of cytarabine or etoposide were additive in inhibiting proliferation, reducing cell viability and increasing apoptosis.
引用
收藏
页码:509 / 512
页数:4
相关论文
共 50 条
  • [41] Megakaryopoiesis in vitro in myelodysplastic syndromes and acute myeloid leukaemia:: effect of pegylated recombinant human megakaryocyte growth and development factor in combination with other growth factors
    Yin, JAL
    Adams, JA
    Brereton, ML
    Hann, A
    Harrison, BD
    Briggs, M
    BRITISH JOURNAL OF HAEMATOLOGY, 2000, 108 (04) : 743 - 746
  • [42] The effect of the chemokine rhMIP-1 alpha, and a non-aggregating variant BB-10010, on blast cells from patients with acute myeloid leukaemia
    OwenLynch, PJ
    Adams, JA
    Brereton, ML
    Czaplewski, LG
    Whetton, AD
    Yin, JAL
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 95 (01) : 77 - 84
  • [43] Effective treatment of elderly acute myeloid leukaemia (AML) with continuous combined granulocyte colony stimulating factor (G-CSF) and single oral chemotherapeutic agents.
    Curnow, JL
    Piccolo, F
    Ward, CM
    Coyle, L
    Fay, K
    Mackinlay, N
    Ramanathan, S
    Arthur, C
    BLOOD, 2004, 104 (11) : 212B - 212B
  • [44] Captopril inhibits in vitro and in vivo the proliferation of primitive haematopoietic cells induced into cell cycle by cytotoxic drug administration or irradiation but has no effect on myeloid leukaemia cell proliferation
    Chisi, JE
    Briscoe, CV
    Ezan, E
    Genet, R
    Riches, AC
    Wdzieczak-Bakala, J
    BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (03) : 563 - 570
  • [45] The Cyclin Dependent Kinase 2, 7 and 9 Inhibitor SNS-032 Has Single Agent Activity in Acute Myeloid Leukaemia Cells and Is Highly Synergistic with Cytarabine.
    Walsby, Elisabeth J.
    Pepper, Chris
    Knapper, Steven
    Burnett, Alan K.
    BLOOD, 2009, 114 (22) : 438 - 438
  • [46] Blast maturity and CD34 expression determine the effects of the differentiating agents KH1060 and 9-cis-retinoic acid on the differentiation and clonogenicity of non-M3 acute myeloid leukaemia cells
    Pallis, M
    Turzanski, J
    Russell, NH
    LEUKEMIA, 1998, 12 (11) : 1741 - 1748
  • [47] Blast maturity and CD34 expression determine the effects of the differentiating agents KH1060 and 9-cis-retinoic acid on the differentiation and clonogenicity of non-M3 acute myeloid leukaemia cells
    M Pallis
    J Turzanski
    NH Russell
    Leukemia, 1998, 12 : 1741 - 1748
  • [48] A SINGLE DOSE OF GEMTUZUMAB-OZOGAMICIN (GO) IN CONSOLIDATION PRIOR TO AUTOLOGOUS TRANSPLANT FOR YOUNGER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID (AML) IS SAFE BUT HAS NO EFFECT ON DISEASE FREE SURVIVAL: INTERIM RESULTS OF EASTERN COOPERATIVE ONCOLOGY GROUP STUDY (E1900)
    Fernandez, H. F.
    Sun, Z.
    Bennett, J. M.
    Paietta, E. M.
    Litzow, M. R.
    Rowe, J. M.
    Tallman, M. S.
    Lazarus, H. M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (02) : 21 - 22
  • [49] FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial
    Russell, Nigel H.
    Wilhelm-Benartzi, Charlotte
    Knapper, Steve
    Batten, Leona M.
    Canham, Joanna
    Hinson, Emily L.
    Overgaard, Ulrik Malthe
    Gilkes, Amanda
    Othman, Jad
    Potter, Nicola
    Dillon, Richard
    Mehta, Priyanka
    Kottaridis, Panagiotis
    Cavenagh, Jamie
    Hemmaway, Claire
    Arnold, Claire
    Freeman, Sylvie D.
    Dennis, Mike
    BLOOD, 2022, 140
  • [50] Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia:: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups
    Amadori, S
    Suciu, S
    Stasi, R
    Willemze, R
    Mandelli, F
    Selleslag, D
    Denzlinger, C
    Muus, P
    Stauder, R
    Berneman, Z
    Pruijt, J
    Nobile, F
    Cassibba, V
    Marie, JP
    Beeldens, F
    Baila, L
    Vignetti, M
    de Witte, T
    LEUKEMIA, 2005, 19 (10) : 1768 - 1773